Traumatic Brain Injury Clinical Trial
Official title:
Phase I Study of Minocycline in a Dose Escalation Study as a Safe, Efficacious Therapeutic Intervention for Moderate and Severe TBI in Humans
The purpose of this study is:
1. To assess the safety and feasibility of minocycline administration after TBI in a dose
escalation study at two different doses over 7 days.
2. To assess the pharmacokinetic characteristics of two different dosing regimens of
minocycline in TBI patients, the effect on biochemical markers of neuroprotective
mechanisms, and effect on neurobehavioral and functional outcome.
3. To begin initial assessment of the efficacy of minocycline as a therapeutic agent for
severe human TBI.
The purpose of this preliminary study is to test the hypothesis that administration of
minocycline to humans with moderate and severe TBI is both safe and feasible in the acute
post-injury setting, and to characterize its disposition and effects on biomarkers of
traumatic CNS injury in a Phase IIa trial. The data collected will serve as the basis for a
larger Phase IIb clinical trial in a randomized placebo-controlled parallel group design, to
investigate further its potential safety and efficacy as a therapeutic agent for severe human
TBI.
Tetracycline derivatives, including doxycycline and minocycline, have been shown to be
neuroprotective when given after traumatic brain injury (TBI) and ischemia in rodents. In
particular, reduced lesion volume and improved neurological outcome have been demonstrated
following minocycline treatment of TBI. The proposed mechanism for these observations is
multifactorial, and includes inhibition of microglial activation, caspase-mediated apoptosis,
and the excitotoxic N-methyl-D-aspartic acid (NMDA) pathway. Because comparable inflammatory,
excitotoxic and apoptotic pathways have also been implicated in human TBI, we hypothesize
that administration of minocycline will confer neuroprotection after moderate to severe TBI
in that milieu as well, with the potential for significant clinical benefit. Minocycline is
highly lipophilic, and thus penetrates the human central nervous system (CNS). In addition,
it has been shown to be safe when used in non-traumatic human neurological disorders.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
Recruiting |
NCT05503316 -
The Roll of Balance Confidence in Gait Rehabilitation in Persons With a Lesion of the Central Nervous System
|
N/A | |
Completed |
NCT04356963 -
Adjunct VR Pain Management in Acute Brain Injury
|
N/A | |
Completed |
NCT03418129 -
Neuromodulatory Treatments for Pain Management in TBI
|
N/A | |
Terminated |
NCT03698747 -
Myelin Imaging in Concussed High School Football Players
|
||
Recruiting |
NCT05130658 -
Study to Improve Ambulation in Individuals With TBI Using Virtual Reality -Based Treadmill Training
|
N/A | |
Recruiting |
NCT04560946 -
Personalized, Augmented Cognitive Training (PACT) for Service Members and Veterans With a History of TBI
|
N/A | |
Completed |
NCT05160194 -
Gaining Real-Life Skills Over the Web
|
N/A | |
Recruiting |
NCT02059941 -
Managing Severe Traumatic Brain Injury (TBI) Without Intracranial Pressure Monitoring (ICP) Monitoring Guidelines
|
N/A | |
Recruiting |
NCT03940443 -
Differences in Mortality and Morbidity in Patients Suffering a Time-critical Condition Between GEMS and HEMS
|
||
Recruiting |
NCT03937947 -
Traumatic Brain Injury Associated Radiological DVT Incidence and Significance Study
|
||
Completed |
NCT04465019 -
Exoskeleton Rehabilitation on TBI
|
||
Recruiting |
NCT04530955 -
Transitioning to a Valve-Gated Intrathecal Drug Delivery System (IDDS)
|
N/A | |
Recruiting |
NCT03899532 -
Remote Ischemic Conditioning in Traumatic Brain Injury
|
N/A | |
Suspended |
NCT04244058 -
Changes in Glutamatergic Neurotransmission of Severe TBI Patients
|
Early Phase 1 | |
Completed |
NCT03307070 -
Adapted Cognitive Behavioral Treatment for Depression in Patients With Moderate to Severe Traumatic Brain Injury
|
N/A | |
Recruiting |
NCT04274777 -
The Relationship Between Lipid Peroxidation Products From Traumatic Brain Injury and Secondary Coagulation Disorders
|
||
Withdrawn |
NCT05062148 -
Fundamental and Applied Concussion Recovery Modality Research and Development: Applications for the Enhanced Recovery
|
N/A | |
Withdrawn |
NCT04199130 -
Cognitive Rehabilitation and Brain Activity of Attention-Control Impairment in TBI
|
N/A | |
Withdrawn |
NCT03626727 -
Evaluation of the Efficacy of Sodium Oxybate (Xyrem®) in Treatment of Post-traumatic Narcolepsy and Post-traumatic Hypersomnia
|
Early Phase 1 |